Fig. 1From: Pathological profiles and clinical management challenges of breast cancer emerging in young women in Indonesia: a hospital-based studyProgression free survival correlated to some parameters in YBCs. PFS of YBCs was significantly shorter (a) in YBCs with skin or chest wall infiltration (T4) compared to those without skin/chest wall infiltration (T1-T3) (median survival 16 vs. 35 months, p = 0.011; HR = 1.89, 95%CI: 1.12–3.21); b in YBCs with positive lymph node infiltration compared to node negative (median survival 24 vs 42 months, p = 0.041; HR = 1.95, 95%CI: 1.05–3.64); c in YBC with hormonal receptor positive compared to negative (median survival 42 vs. 29 months, p = 0.37; HR = 1.64, 95%CI: 1.01–2.67), and (d) in triple-negative YBCs compared to other subtypes (median survival 16 vs 38 months, p = 0.038; HR = 1.66, 95%CI: 1.02–2.72)Back to article page